OmniAb (NASDAQ: OABI) — Company Overview, News & Financial Data
OmniAb specializes in developing antibody-based therapeutics, focusing on oncology and immunology through innovative technology.
OmniAb
OmniAb (NASDAQ:OABI) specializes in leveraging its proprietary technology to discover and develop innovative antibody-based therapeutics for a broad range of diseases. The company thrives on a dynamic platform that includes advanced genetic engineering, immunization, and screening technologies designed to address complex therapeutic challenges. OmniAb's operations revolve around partnerships and collaborations with biopharmaceutical entities, with a mission to expedite the journey from discovery to clinical stages. The company's projects span oncology, immunology, and infectious diseases among other areas, showcasing a versatile and potent approach to tackling severe health issues. Objectively, OmniAb aims to harness its cutting-edge technology to push the boundaries of antibody therapy, optimizing efficacy, safety, and accessibility for patients worldwide.
Snapshot
Operations
Products and/or services of OmniAb
- Antibody discovery platform leveraging transgenic animals for developing human therapeutic antibodies with diverse and optimized immune repertoire.
- Humanized rodent models designed to produce a broad diversity of high-affinity human antibodies, facilitating rapid discovery and development of therapeutic candidates.
- Modular OmniRat, OmniMouse, and OmniFlic platforms, offering diverse options for monoclonal antibody development against challenging targets in multiple therapeutic areas.
- OmniChicken platform, providing unique capabilities for generating antibodies with high specificity and affinity, suitable for a variety of therapeutic applications.
- OmniClic, a specialized platform for the generation of bispecific antibodies, enhancing therapeutic potential through targeted dual-action mechanisms.
- Integrated antibody discovery and optimization services, supporting partners from early-stage research through to pre-clinical development.
OmniAb executive team
- Matthew W. FoehrPresident, CEO & Director
- Kurt A. GustafsonExecutive VP of Finance & CFO
- Charles S. BerkmanChief Legal Officer
- Amechi NwachukuExecutive VP & Chief Operating Officer
- Cia McCaffreySenior Vice President of People & Talent
- Bill HarrimanSenior Vice President of Discovery Partnership Mgt., Technology Development & Operations
- Christel IfflandSenior Vice President of R&D Portfolio Management and Technology Operations
- Yasmina Noubia AbdicheSenior Vice President of Exploratory Research
- Bob ChenSenior Vice President of Discovery Systems
- Todd PettingillVice President of Business Development & Strategy
Key financials
Reported results for OmniAb, in USD.
- Market cap
- 721.1M
- Revenue (TTM)
- 38.5M
- P/E ratio
- —
- EPS (diluted, TTM)
- -0.4
- Dividend yield
- —
- Profit margin
- -115.1%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 18.7M | -71.5M | -64.8M | |
| 26.4M | -74.5M | -62M | |
| 34.2M | -69.4M | -50.6M | |
| 59.1M | -26.6M | -22.3M |